Race Oncology : Investor Presentation - November 2021

Published: 2021-11-23 02:59:12 ET RAC.AX

onlyuseNOVEL RNA-DIRECTED THERAPEUTICS

TO TREAT CANCER AND PROTECT THE HEART

personalInvestor Presentation November 2021

r

DISCLAIMER

onlyInvestment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race

does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This

presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take

into account the investment objectives, financial situation and particular needs of the investor. Before making any investment

in Race, the investor or prospective investor should consider whether such an investment is appropriate to their particular

useinv stment needs, objectives and financial circumstances and consult an investment advisor if necessary. This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. S ch statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

RACE ONCOLOGY LIMITED (ASX:RAC)

2

INVESTOR PRESENTATION

personal

r

WHY INVEST NOW?

only

Clinical stage RNA focused company targeting multiple cancer indications with

estimated annual oncology revenues of >US$2.6 billion

use

Zantrene® first in class, best in class, most clinically advanced FTO inhibitor

personalr

Expanding projects, pipeline and prospects

New formulations to extend Zantrene® utility in solid tumours and beyond

Cardio-protection, an emerging opportunity with significant commercial potential

Multiple short-to-medium term, high-impact inflection points including cardio-

protection and Zantrene® US IND

RACE ONCOLOGY LIMITED (ASX:RAC)

3

INVESTOR PRESENTATION

SIGNIFICANT COMMERCIAL OPPORTUNITIES

only

use

ONCOLOGY

Annual revenue conservatively at

personalr

US$2.6 billion for AML, renal cancer and melanoma alone

Significant revenue potential from other FTO-driven cancers

RACE ONCOLOGY LIMITED (ASX:RAC)

NEW: CARDIO-

PROTECTION

Existing market with millions of patients given anthracyclines each year

Multi-billion dollar addressable market

Market potential of similar magnitude to the FTO opportunity

4

NEW: OTHER RNA

MOLECULES

Expanded opportunities in oncology, cardio-protection and other diseases

INVESTOR PRESENTATION

onlyuseMARKET RATIONALE personalr

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Race Oncology Ltd. published this content on 23 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 November 2021 07:58:03 UTC.